Real-world analysis of extended half-life product posology in hemophilia A: results from a retrospective analysis of medical chart and claims data
Individualization may support improved outcomes in patients unable to achieve satisfactory outcomes on a per-label dosing regimen.
Authors
- Cedric R.J.R. Hermans (ORCID: https://orcid.org/0000-0001-5429-8437)
- John Waller (ORCID: https://orcid.org/0000-0002-7322-991X)
- Steven R. Lentz (ORCID: https://orcid.org/0000-0002-8885-4718)
Institutions
- University of Iowa (US)
- Cliniques Universitaires Saint-Luc (BE)
- Novo Nordisk (Switzerland) (CH)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1080/17474086.2025.2520312
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00